Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.
Alexandra S. Bailey
No relevant relationships to disclose
SuChun Cheng
No relevant relationships to disclose
Eugene D. Kwon
No relevant relationships to disclose
Bradley C. Leibovich
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
Janice P. Dutcher
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
Jeffrey Alan Sosman
No relevant relationships to disclose
Kim Allyson Margolin
No relevant relationships to disclose
Joseph Clark
No relevant relationships to disclose
Nikhil I. Khushalani
Consultant or Advisory Role - Prometheus
Brendan D. Curti
No relevant relationships to disclose
Marc S. Ernstoff
No relevant relationships to disclose
Allan J. Pantuck
No relevant relationships to disclose
Ulka N. Vaishampayan
Consultant or Advisory Role - Dendreon; Janssen Oncology; Novartis; Pfizer
Research Funding - Genentech/Roche; Novartis
Other Remuneration - Dendreon (Speakers Bureau); Genentech/Roche; Janssen Biotech (Speakers Bureau); Medivation (Speakers Bureau); Novartis (Speakers Bureau); Pfizer (Educational Presentation Development); Pfizer (Speakers Bureau)
Theodore Logan
No relevant relationships to disclose
David F. McDermott
Consultant or Advisory Role - Prometheus
Michael B. Atkins
No relevant relationships to disclose